FDA Analysis Of Antidepressant Pediatric Suicidality Data To Be Reviewed Sept. 13-14
This article was originally published in The Pink Sheet Daily
Executive Summary
Joint meeting of Psychopharmacologic and newly formed Pediatric Advisory Committees will review analysis performed by expert group assembled by Columbia University. Future research needs in pediatric suicidality will also be addressed.
You may also be interested in...
FDA Requests Suicidality Event Review For Epilepsy Drugs
FDA is requesting that 14 manufacturers of anti-epileptic drugs re-examine clinical trial data to identify potential suicide-related adverse events. The analyses will be modeled on the agency’s recent re-examination of antidepressant data. FDA’s request to epilepsy drug sponsors follows suicidality signals seen in some trials.
FDA Requests Suicidality Event Review For Epilepsy Drugs
FDA is requesting that 14 manufacturers of anti-epileptic drugs re-examine clinical trial data to identify potential suicide-related adverse events. The analyses will be modeled on the agency’s recent re-examination of antidepressant data. FDA’s request to epilepsy drug sponsors follows suicidality signals seen in some trials.
Antidepressant Suicidality Class Risk Will Be Reviewed By Advisory Committees
FDA releases analysis of pediatric suicidality data for joint meeting of Psychopharmacologic Drugs and Pediatric Advisory Committees. The analysis could result in label changes for antidepressants, FDA Talk Paper says.